Qure.ai

Qure.ai operates at the intersection of radiology AI, digital health, and medical-device software, with a particularly strong emphasis on chest imaging and high-burden diseases such as tuberculosis and lung cancer. Its product portfolio spans qXR for chest X-rays, qER for head CT, qCT-Lung for lung nodules, qMSK for fractures, qTrack for screening-program management, and Aira for frontline clinical decision support. This breadth gives Qure.ai a broader disease and workflow footprint than vendors focused primarily on stroke triage or enterprise radiology orchestration. The company competes for attention with radiology AI providers such as Aidoc, Viz.ai, and Annalise.ai, but differentiates through deployment in resource-constrained settings, cloud and on-premises options, and reported use of qXR across more than 10.7 million scans, 90-plus countries, and 3,100-plus sites. FDA clearances, CE certifications, and partnerships with Microsoft and AstraZeneca support credibility with health systems and global-health programs. Its $133.3 million in cumulative funding and 251–500 employee range indicate substantially greater scale than an early-stage niche developer, although public information does not establish comparative revenue or market share.

Qure.ai’s trajectory reflects a progression from a focused medical-imaging startup into a broader clinical decision-support platform. Founded in 2016, the company raised a $16 million Venture Round in 2020, followed by a $40 million Series C in March 2022 and a $65 million Series D in June 2024. Grants added $4.3 million in February 2022 and $8 million from the Bill & Melinda Gates Foundation in January 2026, bringing cumulative funding to $133.3 million across five rounds. Product development has expanded from qXR and qER into lung-nodule analysis, musculoskeletal imaging, workflow management, and primary-care decision support. The February 2026 launch of FDA-cleared qXR-Detect marked a regulatory and product-scale inflection point, while Aira’s Class IIb CE certification announced in September 2026 extended the company into frontline care. International growth is reinforced by the Microsoft U.S. distribution collaboration and the AstraZeneca CREATE programme. Hiring across business development, regulatory, clinical research, customer success, and engineering suggests continued operational expansion. The August 2025 appointment of Dr. Javier Zulueta and August 2026 appointment of Mihir Bhanushali further indicate investment in clinical strategy and global health execution.